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Abstract 
 
Background 
The immune checkpoint inhibitors (ICIs) have resulted in subgroups of patients with 
metastatic melanoma achieving high quality durable responses. Metastatic melanoma 
survivors are a new population in the era of cancer survivorship. The aim of this study was 
to evaluate metastatic melanoma survivors in terms of health-related quality of life 
(HRQoL), immune related adverse events (irAEs) and exposure to immunosuppressive 
agents in a large single centre in the United Kingdom. 
Methods 
We defined the survivor population as patients with a diagnosis of metastatic melanoma 
who achieved a durable response to an ICI and had been followed up for a minimum of 12 
months from initiation of ICI without disease progression. HRQoL was assessed using SF-36. 
Electronic health records were accessed to collect data on demographics, treatments, irAEs 
and survival. HRQoL data was compared to two norm based datasets. 
Results 
Eighty-four metastatic melanoma survivors were eligible and 87% (N=73) completed the SF-
36. ICI related toxicity of any grade occurred in 92% of patients and 43% had experienced a 
grade 3 or 4 toxicity. Almost half (49%) of the patients required steroids for the treatment of 
ICI related toxicity, while 14% required treatment with an immunosuppressive agent beyond 
steroids.   
Melanoma survivors had statistically significant lower HRQoL scores with regard to physical, 
social and physical role functioning and general health compared to the normative 
population. There was a trend towards inferior scores in patients with previous exposure to 
ipilimumab compared to those never exposed to ipilimumab. 
Conclusions 
Our results show that metastatic melanoma survivors have potentially experienced 
significant ICI related toxicity and experience significant impairments in specific HRQoL 
domains. Future service planning is required to meet this populations unique survivorship 
needs. 
 
  
Background 
The introduction of the immune checkpoint inhibitors (ICIs) has transformed the therapeutic 
arena in metastatic melanoma such that subsets of patients now have the potential to 
achieve high quality durable responses and in some cases cure can be achieved. This has 
translated into an unprecedented number of patients now living with a diagnosis of 
metastatic melanoma. Oncology clinics worldwide are faced with a new population of 
patients, the ‘metastatic melanoma survivors’. Many of the principles and applications of 
cancer survivorship that are common across all survivor populations are relevant to the 
metastatic melanoma survivors.[1, 2] However at a time when exciting new therapies are 
replacing older therapies recognition of tumor-specific and treatment-specific issues that 
limit the survivor’s return to full physical and psychosocial functioning are necessary to 
achieve optimal cancer survivor care.   
Metastatic melanoma survivors can encounter obstacles in restoration and maintenance in 
physical domains of health-related quality of life (HRQoL) due to toxicity from ICIs. The 
immune checkpoints are inhibitory signals that form part of a large network of signalling 
pathways that act as gate keepers to the activation of the immune system and regulate the 
magnitude and duration of the immune response. ICIs are often referred to as ‘the brakes of 
the immune system’. Removing the ‘brakes’ has the potential to unleash the effectors of the 
immune system in an unrestrained manner and result in a class of inflammatory adverse 
events that are unique to ICIs.[3, 4] Frequency of toxicity differs between ICIs. Common 
toxicities include dermatological toxicity, colitis and hepatitis with rarer toxicities including 
myocarditis and neurological toxicity [5]. These physical adverse events have the potential 
to cause significant and persistent morbidity which can occur during therapy but also post 
discontinuation. The mainstay of treatment for immune related adverse events (irAEs) is 
corticosteroids. Immunomodulatory agents such as infliximab and mycophenolate are 
utilized in steroid refractory or resistant cases. These therapies can cause toxicities in their 
own right ranging from issues surrounding glucose tolerance and bone health to viral 
reactivation and hepatotoxicity. Any survivorship pathway for patients treated with an ICI, 
which represents the majority of metastatic melanoma survivors, must account for the 
direct and indirect physical issues irAEs provoke.  
The metastatic melanoma survivor will also encounter psychosocial obstacles to restoration 
of health including uncertainty regarding response to treatment, fear of disease progression 
or recurrence, negative impact on relationships, work and financial concerns and dealing 
with unexpected effects of treatment in daily life.[6] [7] The first patient with metastatic 
melanoma was treated with ipilimumab in a phase 1 trial in 2000. In 2011 Ipilimumab was 
the first ICI to be approved by the FDA and subsequently the EMA for metastatic melanoma. 
The PD-1 inhibitors nivolumab and pembrolizumab were approved for metastatic melanoma 
in 2014. This was followed by the approval of the combination of ipilimumab and nivolumab 
in 2015. Our experience with ICIs in clinical practice is thus relatively limited. Clinical trials 
do not reflect real world populations. In a recent report Donia et al applied the eligibility 
criteria from the pivotal phase III trials of ICIs in metastatic melanoma to the Danish 
metastatic melanoma database and found that 55% of patients would not have met criteria 
for inclusion [8]. This results in a level of uncertainty regarding aspects of the long-term 
follow-up of metastatic melanoma survivors.  The relative infancy of ICIs in clinical practice 
also means there are gaps in our knowledge regarding general health issues with examples 
including fertility and the safety of vaccinations. These uncertainties have the potential to 
result in significant distress for patients, caregivers and other health professional outside 
the oncology domain. 
Though HRQoL and irAEs have previously been characterised and reported from clinical 
trials of patients with metastatic melanoma undergoing treatment with ICIs, no report to 
date has addressed the metastatic melanoma survivors specifically. The aim of this study 
was to examine melanoma patients’ with metastatic disease, who survived at least one year 
from commencing an ICI and describe toxicity profiles during and after ICI therapy, exposure 
to immunosuppressive agents and HRQoL in a large single centre in UK.  
Methods 
Between May 2017 and August 2017 all patients who attended the melanoma clinic in the 
outpatients department and who fulfilled eligibility criteria as defined below were invited to 
fill in the SF-36 questionnaire to assess HRQoL. Patient’s electronic health records were then 
accessed to collect clinical data including patient demographics, systemic therapies, data 
regarding prior toxicity (during and after ICI therapy) and treatment of toxicity and survival 
data.  
Study Population 
We defined survivors as patients, ≥ 18 years of age, who achieved a durable response to an 
ICI and had been followed up for a minimum of 12 months from initiation of ICI without 
progressive disease, having received at least 1 dose of ipilimumab, nivolumab, 
pembrolizumab or ipilimumab + nivolumab in the setting of unresectable stage III 
melanoma or metastatic melanoma as defined by the American joint committee on cancer 
(AJCC ) version 7 staging system. [9] 
‘Durable response to an ICI’ included (1) patients achieving a response as defined by RECIST 
criteria (2) patients who had stable disease (SD) as defined by response evaluation criteria in 
solid tumors (RECIST)  for > 24 weeks and (3) patients who were defined as having clinical 
benefit by their treating physician from ICI in the absence of a RECIST definable 
response.[10, 11] We adopted this broad definition of response in the knowledge that ICIs 
can result in unique patterns of response and as a result patients who derive clinical benefit 
may not fall within the scope of traditional definitions of response.[12]  
Patients with isolated areas of disease progression treated with surgery or radiotherapy 
were included if the remainder of their disease fulfilled our previous definition of response 
and when radiotherapy or surgery was completed no less than 6 weeks from the date of the 
SF-36 form being completed. We decided to include these patients as they reflect ‘real 
world’ immunotherapy survivors and such patients have the potential to have prolonged 
survival despite progressive disease.[13, 14] 
We limited the study to patients who are currently undergoing follow-up in the Melanoma 
unit of a major UK cancer center and who were willing and fit to complete the SF-36 
questionnaire. Fitness was defined as patients who were physically capable of filling in the 
form unaided and those who had sufficient capacity to complete the questionnaire. 
Materials and Data Collection 
Following review by the trusts’ Research and Development department, the study was 
deemed exempt from full review and approval by a research ethics committee and was 
considered to fall under ‘Service Evaluation’ (as per HRA guidance) (HRA, 2016), given the 
focus was not on sensitive information and related instead to the treatments received. 
Aggregated, non-identifiable data only was collated. It was approved by the Trust’s Service 
Evaluation committee (SE), under the Research and Development department.[15] 
Toxicity had been characterised using the immune related adverse events (irAE) criteria and 
graded as per Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. . 
Objective responses were classified using the RECIST criteria as described above.  
The 36-item short form health survey (SF-36) was used to assess patient reported HRQoL 
(Supplementary data). The SF-36 is a validated, self-reported questionnaire covering eight 
domains of HRQoL: vitality, physical functioning, bodily pain, general health perceptions, 
physical role functioning, emotional role functioning, social role functioning and mental 
health.[16] 
All data regarding toxicity, response and survival was collected up until the date the SF-36 
questionnaire was completed to ensure that toxicity and survival data pertained only to the 
period relevant to the HRQoL data. 
 
Data synthesis and Statistical Analysis 
Statistical analysis was performed using SPSS version 24. Progression free survival (PFS) was 
calculated using the date the last line of systemic therapy was commenced to the date of 
progressive disease as defined by RECIST criteria. Median PFS were calculated using the 
Kaplan-Meier method. Differences in SF-36 scores were analysed in pre-planned subgroups 
categorised based on age, sex, any grade toxicity, grade 3 or 4 toxicity, steroid exposure, ICI 
type and ipilimumab exposure. Age based subgroups included: adolescents and young 
adults (AYA) aged 18 to 39 at time of diagnosis, middle-aged aged 40-65 and the elderly 
aged > 65 years. Dichotomized subgroups (e.g. gender, treatment status) were compared 
using independent t-tests. Subgroups with 3 or more categories (e.g. age, ICI type) were 
compared using an ANOVA test. Norm based scores from 2 sources were compared to 
HRQoL outcomes from melanoma survivors: the British office of national statistics (ONS) 
omnibus survey and the Oxford healthy life survey, both from 1992[17-19]. Demographic 
data on norm based sources is presented in the Supplementary data. Comparison to norm 
based data was performed using one-sample t-test.  
Results 
Between January 2011 and August 2016 481 patients with metastatic melanoma were 
treated with an ICI. 84 patients (17.5%) met inclusion criteria to be considered part of the 
survivor population. 73 patients (87%) were willing and fit to complete the SF-36 
questionnaire. The 11 patients for whom we do not have HRQoL data include: 8 patients 
who were either uncontactable or declined to partake, 2 patients who were inpatients in 
hospital during the data collection period (1 was an inpatient for treatment of ICI induced 
toxicity, the other admission was unrelated to ICI therapy or melanoma) and 1 patient who 
was not fit to fill in the SF-36 questionnaire for reasons unrelated to melanoma or its 
treatment.  
Patient Demographics 
Patient demographics are presented in Table 1.  
At the time of analysis 29.7% of patients were still actively undergoing therapy with an ICI. 
39% of patients had stopped treatment due to toxicity. 28.5% of patients had stopped 
treatment as they had completed therapy as per local guidelines (i.e. 4 cycles of ipilimumab, 
2 years of PD-1 inhibitor monotherapy or combination ipilimumab and nivolumab for 4 
cycles followed by nivolumab maintenance up to 2 years). Two percent of patients stopped 
treatment as it was their preference to do so. Patients who have stopped ICI before they 
completed therapy received a median of 2.1 months (range 0.4-34.6) of systemic therapy.  
Survival 
Response and responses presented in Table 1. At the time of analysis median follow-up was 
25 months (95% CI 20.8-29.1). 46% of patients had been followed-up for 12-24 months, 18% 
for 25-36 months and 36% for over 36 months since commencing an ICI. 76 patients had a 
response by RECIST criteria translating into an objective response rate (ORR) of 90%. 8 
patients (10%) had SD as best response.  
12 patients (14%) had experienced isolated sites of progression that had been treated with 
surgery or radiotherapy. Details of these patients’ best response and treatments are 
presented in supplementary data. Median PFS in this group was 10 months (95% CI 7.7-
12.3). Following surgery or radiotherapy this subgroup has been followed for a median of 13 
months (range 4-31) without further intervention for disease progression. 
Toxicity 
Rate, class and treatment of irAEs for all patients, patients exposed to ipilimumab and 
patients solely exposed to PD-1 inhibitors are presented in Table 2.  
14% of patients ultimately required therapies beyond steroids for toxicity including 
infliximab (n=5), mycophenalate (n=4), vedolizumab (n=1), sulfasalazine (n=1), methotrexate 
(n=1), eltrombopag (n-1), intravenous immunoglobulins (n=1) and plasmapheresis (n=1).  
Twelve patients experienced an irAE having discontinued an ICI. Four such patients 
developed vitiligo and no other irAE. Characteristics of the remaining 8 patients are 
presented In Table 3.  
HRQoL 
Table 4 shows scores for the melanoma survivor’s HRQoL domains as compared to the 
British ONS omnibus survey and the Oxford healthy life survey norm based data [17-19]. The 
melanoma survivors had statistically significant lower scores compared to both norm based 
datasets in domains including physical functioning, social functioning, physical role 
functioning and general health. There was no statistically significant difference between the 
melanoma survivors scores compared to the norm based data in domains including mental 
health and bodily pain. For emotional role functioning and vitality the melanoma survivors 
had numerically inferior scores compared to the norm based data but this only reached 
statistical significance in comparison to the British ONS survey.  
In the subgroup analysis statistically significant differences in physical functioning scores 
were noted when patients were categorised based on age (Supplementary data). Scores 
were consistently numerically inferior in elderly patients across all domains which 
contribute to the physical component score, physical role functioning, general health and 
bodily pain. These numerical differences resulted in a statistically significant difference in 
the physical component summary between age groups. 
There was considerable variation in scores between patients depending on which ICI they 
had received (Figure 1). There was a trend towards inferior scores in patients with previous 
exposure to ipilimumab but this did not reach statistical significance (Figure 2). No 
statistically significant difference in scores were noted in the remainder of the subgroup 
comparisons including sex, treatment status (on/off treatment), any grade toxicity, grade 3 
or 4 toxicity and steroid exposure. 
Discussion 
To our knowledge this is the first report to evaluate HRQoL in metastatic melanoma 
survivors, showing that survivors have the potential to encounter impairment in both 
physical and mental HRQoL domains and represent a unique population with specific 
survivorship needs.  
HRQoL has been measured in a number of trials of ICIs in melanoma. To date four 
randomised trials have reported patient reported HRQoL beyond the initial 12 weeks of 
treatment.[20] In Checkmate 066, a randomised phase III trial comparing nivolumab to 
chemotherapy, EORTC-QLQ-C30 scores were maintained throughout follow-up for 
nivolumab up to a maximum of 73 weeks. There was statistically significant improvements 
in EQ-5D scores from baseline at weeks 7 and 49 and clinically meaningful improvements at 
weeks 37, 61 and 67[21]. In Keynote 006 patients treated with pembrolizumab, irrespective 
of dose, had smaller declines in EORTC-QLQ-C30 scores between baseline and week 12 as 
compared to ipilimumab (p<0.001). At week 36 for patients who were still on treatment 
EORTC-QLQ-C30 scores had improved across all treatment arms and were grossly 
comparable between treatment groups.[22, 23] In Checkmate 069 no difference was 
detected between patients who were treated with single agent ipilimumab and combination 
ipilimumab and nivolumab.[24] In checkmate 067[25] an initial non-clinically significant 
decline in patient report HRQoL scores  was followed by a return to baseline across all three 
treatment arms of nivolumab in combination with ipilimumab, ipilimumab monotherapy 
and nivolumab monotherapy. In each of these four trials HRQoL data failed to capture 
patients who discontinued treatment due to toxicity and these was no comparison to norm 
based data. 
In our survivor cohort stratification by age resulted in clinically meaningful and statistically 
significant differences in scores in physical health domains. Elderly patients reported the 
worst scores.  Though recent data would suggest elderly patients do not demonstrate an 
increased risk of incurring irAEs compared to the remainder of the population there remains 
the possibility that they possess reduced physiological reserve and thus toxicity may result 
in a greater impact on HRQoL [26, 27]. The elderly population is not well represented in 
previous reports of HRQoL or the clinical trial setting in general.[26, 28] Limitations placed 
on performance status and organ function mean that elderly patients who do qualify for 
inclusion may not be representative of the real-world population.  Moreover performance 
status is a limited tool for evaluating elderly patients and doesn’t encompass important 
parameters such as frailty  Comprehensive geriatric assessment may be more effective 
during and after therapy and should be incorporated into future prospective clinical trials 
[29].  
We found no difference in HRQoL in patients who experienced toxicity and those who 
experienced no toxicity irrespective of grade and management. This analysis is limited by 
only six patients in our cohort not experiencing any toxicity thus these results should be 
interpreted with caution. A possible interpretation is that though toxicity is a key 
contributor to HRQoL the patient experience has many dimensions that are currently not 
well captured. We observed a trend towards inferior HRQoL scores in patients exposed to 
ipilimumab in domains related to physical functioning. This may be related to the fact that 
these patients experienced more grade 3 or 4 toxicity than patients who never received 
ipilimumab. In our cohort hypophysitis (n=6) and neurotoxicity (n=5) only occurred in 
patients exposed to ipilimumab. Ipilimumab induced hypophysitis is frequently a chronic 
condition requiring life-long steroid replacement.[30, 31] Neurological toxicity has the 
potential to cause significant morbidity [32]. Toxicities of the same grade can affect HRQoL 
discordantly but this is not reflected in current grading systems.  
The SF-36 questionnaire is generic and not cancer specific. This represents a limitation of 
our study. There are cancer-specific HRQoL questionnaires available (e.g. EORTC QLQ-C30) 
that has been favoured for use in clinical trials of ICIs. In terms of being cancer specific, 
tumor specific, stage specific and treatment specific all current HRQoL questionnaires 
available for use in clinic practice are limited. Melanoma specific modules in HRQoL 
questionnaires are largely based on long-term sequelae of surgery and though these are 
contributory to impaired HRQoL no survey directly deals with the long term complications of 
metastatic melanoma or ICI therapy. A study currently underway in Toronto aims to develop 
a tool based on the Functional assessment in cancer (FACT) tool that is specific to patients 
undergoing treatment with immunotherapy (NCT02651831) and would thus be more 
sensitive and relevant to metastatic melanoma survivors. Collection of patient-reported 
outcomes (PRO) in research and clinical practice is important as it can facilitate patient 
centered communication, informed decision making, symptom monitoring and will help to 
provide patients’ with the best supportive care. In a recent study, Basch et al demonstrated 
a 5 month overall survival benefit for patients with metastatic solid tumors undergoing PRO 
monitoring compared to patients receiving standard care (HR 0.83, 95% CI 0.70-0.99, 
p=0.04).[33]  
Our study is limited by the usage of SF36 questionnaire version 1, newer versions are 
available. The most recent normative data for the UK population assessed using version 1 
was from 1992. This may not be representative of current populations. Whilst The SF-36 
questionnaire includes a mental health component, it may be useful in future studies to 
expand upon this with tools to measure sleep disturbance, distress, anxiety and fear more 
comprehensively. Our study is limited in that it is cross-sectional in design which hinders the 
determination of causal associations. There is considerable patient to patient variability in 
factors that can contribute to impairment in HRQoL in metastatic melanoma survivors. 
These may include severity, timing and chronicity of toxicity as well as quality, timing and 
durability of response. It is thus not feasible to capture the many potential facets of HRQoL 
at a single time point. Longitudinal data collection from diagnosis would allow HRQoL to be 
measured in parallel with key events in treatment and follow-up and would thus be more 
informative.  
 
Conclusions 
Clinical trial data to date has limited applicability to the survivor population defined in this 
study owing to limited follow-up time and exclusion of patients who discontinued ICI due to 
toxicity before a censoring event. Metastatic melanoma survivors have potentially 
experienced significant irAEs during treatment resulting in chronic conditions, exposure to 
significant doses of steroids or exposure to other immunomodulatory drugs and thus may 
encounter long-term sequelae to their cancer and cancer treatment. Our cohort of 
metastatic melanoma survivors demonstrated significant impairments in physical and 
mental domains of HRQoL compared to healthy controls. Within our survivorship population 
we found that elderly patients were a subgroup that had an increased potential for inferior 
patient reported HRQoL outcomes. We strongly support the recognition of the metastatic 
melanoma survivors as a distinct population that warrant comprehensive longitudinal 
evaluation with particular focus in area of HRQoL.  Future service planning is required to 
meet these patients unique survivorship needs. 
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TABLE 1 
PATIENT DEMOGRAPHICS 
 N = 84 % 
MEDIAN AGE years(range) 65 (22-86) 
MALE 54 (64) 
FEMALE 30 (36) 
HISTOLOGY 
CUTANEOUS 74 (88) 
MUCOSAL 2 (2) 
UNKNOWN 8 (10) 
STAGE 
IIIC UNRESEACTABLE 1 (1) 
M1a 11 (13) 
M1b 14 (17) 
M1c 58 (69) 
BRAIN METASTASES 11 (13) 
LINES OF THERAPY 
1 39 (46) 
2 30 (36) 
 ≥ 3 15 (18) 
LINES OF ICI 
1 51 (61) 
2 31 (37) 
 ≥ 3 2 (2) 
MOST RECENT ICI 
IPILIMUMAB 16 (19) 
PEMBROLIZUMAB 31 (37) 
NIVOLUMAB 18 (21) 
IPILIMUMAB+NIVOLUMAB 12 (14) 
BLINDED CLINICAL TRIAL(A) 7 (8) 
PRIOR SYSTEMIC THERAPY 
BRAF +/- MEK INHIBITOR 15 (18) 
IPILIMUMAB 32 (38) 
PEMBROLIZUMAB 1 (1) 
NIVOLUMAB 1 (1) 
IPILIMUMAB + NIVOLUMAB 1 (1) 
CHEMOTHERAPY 10 (12) 
OTHER 2 (2) 
BRAF MUTANT 30 (36) 
LDH < ULN 60 (71) 
LDH ≥ ULN 24 (29) 
ECOG AT START OF ICI 
0/1 81 (96) 
≥ 2 3 (4) 
AUTOIMMUNE DISEASE 8 (10) 
RESPONSES & SURVIVAL 
CR 36 (43) 
PR 40 (48) 
OR 76 (90) 
SD 8 (10) 
PD(B) 13 (15) 
ICI IMMUNE CHECKPOINT INHIBITOR, LDH LACTATE 
DEHYDROGENASE, (A) ARMS: IPILIMUMAB + NIVOLUMAB, 
IPILIMUMAB, NIVOLUMAB, CR COMPLETE RESPONSE, PR PARTIAL 
RESPONSE, OR OBJECTIVE RESPONSE, SD STABLE DISEASE, PD 
PROGRESSIVE DISEASE (B) PROGRESSIVE DISEASE FOLLOWING INITIAL 
OBJECTIVE RESPONSE OR STABLE DISEASE 
   
TABLE 2 
Immune related Adverse Events 
irAE 
(A)                               (B) (C)  
ALL PATIENTS  (N=84) IPILIMUMAB  # (N=59) 
PD-1 INHIBITOR ## 
(N=17) 
ANY GRADE 
(%) 
GRADE 3/4 
(%) 
STEROID* 
(%) 
IMMUNO-
MODULATO
RY** 
(%) 
ANY 
GRADE 
GRADE 3 
OR 4 
ANY GRADE 
GRADE 3 
OR 4 
TOTAL 77 (92) 36 (43) 41 (49) 12 (14) 54 (92) 30 (51) 16 (94) 6 (35) 
COLITIS 25 (30) 19 (23) 23 (27) 5 (6) 19 (32) 14 (24) 4 (24) 3 (18) 
HEPATITIS 16 (19) 6 (7) 12 (14) 4 (5) 14 (24) 5 (8) 2(17) 1 (6) 
MSK 23 (27) 4 (5) 5 (6) 2 (2) 17(29) 4 (7) 5(29) 0 (0) 
NEPHRITIS 3 (4) 3 (4) 3 (4) 1 (1) 2(3) 2 (3)  1(6) 1 (6) 
DERMATOLOGICAL 59 (70) 10 (12) 26 (31) 0 (0) 36 (61) 7 (19) 14 (82) 2 (12) 
ENDOCRINE 26 (31) 6 (7) 6 (7) 0 (0) 21 (36) 5 (8) 5 (29) 1 (6) 
THYROID 17 (20) 0 (0) 0 (0) 0 (0) 13 (22) 0 (0) 4 (24) 0 (0) 
PITUITARY 6 (7) 2 (2) 2 (2) 0 (0) 6 (10) 2 (2) 0 (0) 0 (0) 
PNEUMONTIS 4 (5) 1(1) 2 (2) 0 (0) 3(5) 1 (2) 1 (6) 0 (0) 
NEUROLOGICAL 5 (6) 2(2) 2 (2) 2 (2) 5(8) 2 (3) 0 (0) 0 (0) 
* THEREPEUTIC DOSES OF CORTICOSTEROIDS USED TO MANAGE TOXICITY, ** IMMUNOMODULATORY AGENTS USED FOR THE 
MANAGEMENT OF TOXICITY BEYOND CORTICOSTEROIDS, MSK MUSCULOSKELETAL TOXICITY ARTHRITIS, ARTHRALGIA, MYALGIA, # 
EXPOSED TO IPILIMUMAB ## NEVER EXPOSED TO IPILIMUMAB ONLY PD-1 INHIBITORS 
TABLE 2 presents rates of toxicity in (A) the total survivor cohort, (B) in patients who received treatment with ipilimumab either a 
monotherapy or in combination with a PD-1 inhibitor and (C) patients who received a PD-1 inhibitor. 
(A) Rates of immune related adverse events (irAEs) are presented for patients with any grade toxicity and grade 3 or 4 toxicity. Rates of 
irAEs that required steroids for treatment irrespective of grade are presented (STEROID) as are rates of irAEs that untimely required 
treatment with an immunomodulatory agent distinct from steroids (IMMUNO-MODULATORY). 
(B) Rates of irAEs in patients who received ipilimumab during the course of their cancer therapy. 
(C) Rates of irAEs in patients who received a PD-1 monotherapy during the course of their cancer therapy and were never exposed to 
ipilimumab. 
   
TABLE 3 
Patients who developed irAEs following discontinuation of immune checkpoint inhibitors 
ICI 
Reason for 
discontinuation 
Cycles 
ICI 
irAE before 
discontinuation (grade) 
irAE post 
discontinuation (grade) 
Onset irAE post 
discontinuation 
(months) 
Treatment 
Best 
response 
PEMBROLIZUMAB irAE 13 
Colitis (G2) 
Rash (G1) 
Arthralgia (G3) 
Myocarditis (G2) 8.1 
No intervention 
required, 
monitored 
SD 
IPILIMUMAB + 
NIVOLUMAB 
irAE 2 
Aseptic Meningitis (G2) 
Hepatitis (G3) 
Colitis (G3) 
Arthralgia (G2) 7.4 Steroids CR 
PEMBROLIZUMAB 
Patient 
preference 
5 
Rash (G1) 
Hepatitis (G2) 
Arthralgia (G1) 5.8 Analgesia PR 
PEMBROLIZUMAB irAE 19 
Colitis (G3) 
Arthralgia (G1) 
Hepatitis (G3) 3.1 Steroids SD  
PEMBROLIZUMAB irAE 34 
Labyrinthitis (G2) 
Hepatitis (G3) 
Hypothyroidism (G2) 
Pruritus (G2) 
Arthralgia (G3) 4.9 
Steroids 
Methotrexate 
CR 
NIVOLUMAB irAE 3 Colitis (G3) Rash (G3) 11.0 Topical steroids CR 
IPILIMUMAB + 
NIVOLUMAB 
irAE 1 
Rash + Pruritus (G3) 
Hepatitis (G3) 
Hypothyroidism (G2) 
Vitiligo (G1) 
Arthralgia (G1) 7.9 Analgesia CR 
PEMBROLIZUMAB irAE 2 Nephritis (G3) 
Arthralgia (G2) 
Rash + Pruritus (G2) 
8 
12.6 
Intra-articular 
steroids 
PR 
TABLE 3 Presents immune related adverse events that occurred in patients who discontinued an immune checkpoint inhibitor  
irAE immune related adverse event, ICI immune checkpoint inhibitor, SD stable disease, CR complete response, PR partial response, G grade. 
   
TABLE 4 SF-36 SCORES FOR SURVIVOR POPULATION COMPARED TO NORM BASED DATA[18, 19, 34] 
 PATIENTS 
(MEAN SF-36) 
OXFORD 
(MEAN SF-36) 
95% CI 
(LOWER) 
95% CI 
(UPPER) 
Pa 
ONS  
(MEAN SF-36) 
95% CI 
(LOWER) 
95% CI 
(UPPER) 
Pb 
Physical 
functioning 
74.9 88.4 -20.3 -6.5 .000 89.6 -21.5 -7.7 .000 
Social 
functioning 
80.3 88 -13.6 -1.7 .011 89 -14.6 -2.7 .005 
Role physical 69.1 85.5 -29.1 -9.6 .000 84.2 -24.8 -5.3 .003 
Role emotional 78.5 82.9 -13.3 4.5 .333 88 -18.4 -0.53 .038 
Mental health 73.5 73.8 -4.5 
3.9 
.890 76.6 -7.3 1.2 .155 
Energy/vitality 55.8 61.1 -11.2 0.74 .085 64.7 -14.8 -2.8 .004 
Pain 79.4 81.5 -8.1 
4.04 
.505 82.5 -9.1 3.04 .322 
General health 65.3 73.5 -12.9 -3.4 .001 74 -13.4 -3.9 .001 
MEAN SF-36 SCORES FOR METASTATIC MELANOMA SURVIVOR POPULATION COMPARED TO OXFORD HEALTHY LIFESTYLE SURVEY 
NORMALISED DATA AND THE BRITISH OFFICE OF NATIONAL STATISTICS (ONS) FORM BASED SCORES. a COMPARISON OF STUDY 
POPULATION WITH OXFORD NORM BASED DATA b COMPARISON OF STUDY POPULATION AND ONS NORM BASED DATA 
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SUPPLEMENTARY DATA 
PATIENTS WITH ISOLATED SITES OF PROGRESSION 
Treatment 
ICI 
ongoing 
Response 
Time to PD 
(months) 
Description 
Follow-up 
(months) 
Ipilimumab N PR 9 Multiple isolated relapses surgically resected including; retroperitoneal mass, axillary LN, 
cervical LN, pelvic LN, omental nodule.  
24 
Ipilimumab N PR 10 Isolated relapse in mesentery resected, new brain metastases treated with cyberknife, 
ongoing monitoring slowly growing mesenteric nodule.  
31* 
Ipilimumab N PR 9 Isolated pulmonary metastases treated with SRS. 22 
Ipilimumab N SD 12 Resection isolated site soft tissue recurrence.  16 
Nivolumab N PR 31 Isolated pulmonary metastases treated with SRS.  15 
Pembrolizumab 
 
Y CR 11 
Resection isolated site soft tissue recurrence. 
14 
Pembrolizumab 
 
N SD 6 
Resection isolated LN with PD, Lobectomy for slowly progressive pulmonary metastases.  
4 
Nivolumab 
 
N PR 10 
Pulmonary relapse treated with resection and SRS.  
13 
Pembrolizumab 
 
Y PR 13 
Isolated site of PD in pelvic LN treated with SRS. 
12 
Pembrolizumab 
 
Y PR 5 
Isolated site of PD in acetabulum treated with SRS.  
10 
Ipilimumab 
 
N CR 37 
Resection isolated liver lesion  
5 
Pembrolizumab 
 
Y PR 22 
Slow PD in isolated vertebral lesion resected  
4 
Patients who had isolated sites of progression post ICI treatment that were then treated with radiotherapy or surgery. ICI Immune checkpoint inhibitor, PD 
Progressive disease, PR Partial response, CR Complete response, SD Stable disease, LN Lymph node, SRS Stereotactic radiosurgery, *Time from last 
intervention for isolated site of progression.  
 
  
 
 
 
 
 
 
 
  
Supplementary Data 
British office of national statistics (ONS) omnibus survey and the Oxford healthy life 
survey norm based data[18] 
 
Oxford 
(n=9332) 
ONS 
(n=2051) 
Age range 
< 65 9332 (100%) 1553 (76%) 
 ≥ 65 0 (0%) 498 (24%) 
Gender 
Male 4229 (45%) 929 (45%) 
Female 5103 (55%) 1122 (55%) 
 
  
  
SF-36 scores for physical domains for patients subcategorised by age. AYA adolescents and young adults 
